Meeting
2021 Genitourinary Cancers Symposium
Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).
Authors
Maha H. A. Hussain
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
Maha H. A. Hussain , Cora N. Sternberg , Eleni Efstathiou , Karim Fizazi , Qi Shen , Xun Lin , Jennifer Sugg , Joyce Leta Steinberg , Bettina Noerby , Ugo De Giorgi , Neal D. Shore , Fred Saad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02003924
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 94)
DOI
10.1200/JCO.2021.39.6_suppl.94
Abstract #
94
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.
First Author: Ugo De Giorgi
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb
Poster
2022 ASCO Annual Meeting
![The association of germline<em> HSD3B1</em> genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].](https://d201v5jt9ylckg.cloudfront.net/288/14370/212152/212152_A1803_poster_pv.jpg)
The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
First Author: Nima Sharifi
Poster
2020 ASCO Virtual Scientific Program
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Karim Fizazi